Search
Ethinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigationalEthinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...
Mixtures: PIL KB HARMONIS, PIL KB I KOMBINASIStrontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnStrontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have shown that strontium ranelate can slow down the progression of osteoarthritis of the knee. This agent presents an atypical mec...
Phenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedPhenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other...
Istisociclib
go.drugbank.com/drugs/DB21703InvestigationalIstisociclib is under investigation in clinical trial NCT04718675 (A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer
Cholecalciferol
go.drugbank.com/drugs/DB00169ApprovedInvestigationalNutraceuticalVitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight . Both the endogenous form of vitamin D (that results fro...
Custirsen
go.drugbank.com/drugs/DB05487InvestigationalCustirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth a...
Fisogatinib
go.drugbank.com/drugs/DB16167InvestigationalFisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalIt is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.